|
1
|
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
|
J Natl Cancer Inst
|
2004
|
6.55
|
|
2
|
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.
|
Nat Med
|
2006
|
4.42
|
|
3
|
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
|
J Natl Cancer Inst
|
2005
|
4.25
|
|
4
|
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
|
Blood
|
2007
|
3.94
|
|
5
|
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
|
Cancer Res
|
2008
|
3.32
|
|
6
|
Visualizing hepatitis C virus infections in human liver by two-photon microscopy.
|
Gastroenterology
|
2009
|
3.07
|
|
7
|
Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study.
|
Mod Pathol
|
2004
|
2.39
|
|
8
|
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
|
J Natl Cancer Inst
|
2007
|
2.11
|
|
9
|
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.
|
Blood
|
2006
|
1.93
|
|
10
|
Hazard rates of recurrence following diagnosis of primary breast cancer.
|
Breast Cancer Res Treat
|
2005
|
1.85
|
|
11
|
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.
|
J Virol
|
2007
|
1.70
|
|
12
|
The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.
|
Am J Clin Oncol
|
2007
|
1.43
|
|
13
|
Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women.
|
Int J Cancer
|
2002
|
1.14
|
|
14
|
Pregnancy, hormonal contraceptive use, and HIV-related death in Rwanda.
|
J Womens Health (Larchmt)
|
2007
|
1.07
|
|
15
|
Stepped-care, community clinic interventions to promote mammography use among low-income rural African American women.
|
Health Educ Behav
|
2004
|
1.06
|
|
16
|
Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung.
|
Clin Cancer Res
|
2002
|
1.04
|
|
17
|
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
|
Mol Cancer Ther
|
2006
|
1.02
|
|
18
|
The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.99
|
|
19
|
Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.
|
Clin Cancer Res
|
2014
|
0.99
|
|
20
|
Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma.
|
Urology
|
2007
|
0.99
|
|
21
|
Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.
|
J Immunother
|
2006
|
0.95
|
|
22
|
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
|
Breast Cancer Res Treat
|
2006
|
0.94
|
|
23
|
Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells.
|
Clin Cancer Res
|
2011
|
0.92
|
|
24
|
Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus.
|
Int J Biochem Mol Biol
|
2012
|
0.86
|
|
25
|
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.85
|
|
26
|
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.
|
Breast Cancer Res Treat
|
2009
|
0.85
|
|
27
|
Case-matching analysis of head and neck squamous cell carcinoma in racial and ethnic minorities in the United States--possible role for human papillomavirus in survival disparities.
|
Head Neck
|
2011
|
0.83
|
|
28
|
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.
|
Breast Cancer Res Treat
|
2005
|
0.83
|
|
29
|
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
|
Leuk Res
|
2013
|
0.83
|
|
30
|
A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation.
|
Breast Cancer Res Treat
|
2012
|
0.81
|
|
31
|
T cell responses in HIV type 1-infected adolescent minorities share similar epitope specificities with whites despite significant differences in HLA class I alleles.
|
AIDS Res Hum Retroviruses
|
2003
|
0.81
|
|
32
|
E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7.
|
Mol Carcinog
|
2005
|
0.80
|
|
33
|
Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma.
|
Clin Lymphoma Myeloma
|
2006
|
0.80
|
|
34
|
Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokers.
|
Chest
|
2003
|
0.79
|
|
35
|
Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.
|
Future Oncol
|
2014
|
0.77
|
|
36
|
Apoptosis induction by the core biopsy procedure.
|
J Clin Oncol
|
2005
|
0.77
|
|
37
|
Characterization of promoter elements regulating the expression of the human neurotensin/neuromedin N gene.
|
J Biol Chem
|
2010
|
0.77
|
|
38
|
Maternal plasma viral load and neutralizing/enhancing antibodies in vertical transmission of HIV: a non-randomized prospective study.
|
Virol J
|
2005
|
0.76
|
|
39
|
Everolimus in HR-positive advanced breast cancer.
|
N Engl J Med
|
2012
|
0.76
|
|
40
|
Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2003
|
0.75
|